Class I phosphoinositide 3-kinase and mechanistic target of rapamycin complex 1 and 2 (Class I PI3K and mTORC1/2)

Class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) complexes 1 and 2 are central components of the PI3K/AKT/mTOR signaling pathway, which regulates essential cellular processes including growth, proliferation, survival, and metabolism [13, 17, 20]. Class I PI3Ks are lipid kinases that generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), while mTOR is a serine/threonine kinase that functions within two distinct multi-protein complexes: mTORC1, which regulates protein synthesis and nutrient sensing, and mTORC2, which contributes to full AKT activation [8, 13, 23]. Dysregulation of this pathway, often through PIK3CA mutations or PTEN loss, is a hallmark of many human cancers and contributes to therapeutic resistance [18, 19, 24]. Dual inhibitors targeting both Class I PI3K and the mTOR kinase domain are developed to achieve more comprehensive pathway blockade than single-node inhibitors, specifically by preventing the compensatory feedback activation of AKT typically observed with mTORC1-selective inhibition [6, 7, 16]. While these dual agents show potent antitumor activity in preclinical models, their clinical utility is often limited by on-target toxicities such as hyperglycemia and gastrointestinal distress [12, 14, 19].

Other names

PI3K/mTORDual PI3K/mTOR targetPhosphatidylinositol 3-kinase and mammalian target of rapamycinPI3K/AKT/mTOR pathway

Dual inhibition of Class I phosphoinositide 3-kinase (PI3K) isoforms and the mechanistic target of rapamycin (mTOR) kinase, effectively blocking both mTORC1 and mTORC2 complexes to prevent compensatory feedback signaling.